Skip to main content
Research
  1. Queen Mary University of London
  2. Research
  3. Publications

Publications: DR Alessandro Agnarelli

Back to Search
Agnarelli A, Buckley-Benbow L, Ozgencil M, Lad M, Ampah KK, Kalinka A, Belan O, Maslen S et al. ( 2025 ) . The genetic and biochemical basis of human leading strand synthesis . Nature Communications vol. 17 , ( 1 )
Buckley-Benbow L, Agnarelli A, Bellelli R ( 2025 ) . ‘Where is my gap’: mechanisms underpinning PARP inhibitor sensitivity in cancer . Biochemical Society Transactions vol. 53 , ( 01 ) 225 - 234 .
Hill BR, Ozgencil M, Buckley-Benbow L, Skingsley SLP, Tomlinson D, Eizmendi CO, Agnarelli A, Bellelli R ( 2024 ) . Loss of POLE3-POLE4 unleashes replicative gap accumulation upon treatment with PARP inhibitors . Cell Reports vol. 43 , ( 5 )
Agnarelli A, Betrán AL, Papakyriakou A, Vella V, Samuels M, Papanastasopoulos P, Giamas C, Mancini EJ et al. ( 2023 ) . The Inhibitory Properties of a Novel, Selective LMTK3 Kinase Inhibitor . International Journal of Molecular Sciences vol. 24 , ( 1 )
Agnarelli A, Vella V, Samuels M, Papanastasopoulos P, Giamas G ( 2022 ) . Incorporating Immunotherapy in the Management of Gastric Cancer: Molecular and Clinical Implications . Cancers vol. 14 , ( 18 )
Agnarelli A, Mitchell S, Caalim G, Wood CD, Milton‐Harris L, Chevassut T, West MJ, Mancini EJ ( 2022 ) . Dissecting the impact of bromodomain inhibitors on the Interferon Regulatory Factor 4‐MYC oncogenic axis in multiple myeloma . Hematological Oncology vol. 40 , ( 3 ) 417 - 429 .
Agnarelli A, Omari KE, Duman R, Wagner A, Mancini EJ ( 2021 ) . Phosphorus and sulfur SAD phasing of the nucleic acid-bound DNA-binding domain of interferon regulatory factor 4 . Acta Crystallographica Section F: Structural Biology Communications vol. 77 , ( Pt 7 ) 202 - 207 .
Garcia-Gil M, Turri B, Gabriele M, Pucci L, Agnarelli A, Lai M, Freer G, Pistello M et al. ( 2021 ) . Protopine/Gemcitabine Combination Induces Cytotoxic or Cytoprotective Effects in Cell Type-Specific and Dose-Dependent Manner on Human Cancer and Normal Cells . Pharmaceuticals vol. 14 , ( 2 )
Agnarelli A, Chevassut T, Mancini EJ ( 2018 ) . IRF4 in multiple myeloma—Biology, disease and therapeutic target . Leukemia Research vol. 72 , 52 - 58 .
Agnarelli A, Natali M, Garcia-Gil M, Pesi R, Tozzi MG, Ippolito C, Bernardini N, Vignali R et al. ( 2018 ) . Cell-specific pattern of berberine pleiotropic effects on different human cell lines . Scientific Reports vol. 8 , ( 1 )
Back to Search